ALNYLAM PHARMACEUTICALS, INC. ($ALNY)
Filing Information
| Accession Number | 0001735276-26-000051 |
|---|---|
| Form Type | 4 |
| Filing Date | Mar 5, 2026 |
| Document | View SEC Filing |
Transactions
16
Total Shares
15,043
Total Value
$1,051,773.01
P&L
+inf% (+$3,681,420.81)
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CSO & EVP, Head of Research | Common Stock | โ | Mar 2, 2026 | Grant/Award | 3,688 | $0.00 | $0.00 | 25,110 | Direct | โ | View Details | |
CSO & EVP, Head of Research | Common Stock | โ | Mar 2, 2026 | Sale | 47 | $323.62 | $15,210.14 | 25,063 | Direct | โ | View Details | |
CSO & EVP, Head of Research | Common Stock | โ | Mar 2, 2026 | Sale | 90 | $324.65 | $29,218.50 | 24,973 | Direct | โ | View Details | |
CSO & EVP, Head of Research | Common Stock | โ | Mar 2, 2026 | Sale | 258 | $325.63 | $84,012.54 | 24,715 | Direct | โ | View Details | |
CSO & EVP, Head of Research | Common Stock | โ | Mar 2, 2026 | Sale | 392 | $326.81 | $128,109.52 | 24,323 | Direct | โ | View Details | |
CSO & EVP, Head of Research | Common Stock | โ | Mar 2, 2026 | Sale | 329 | $327.67 | $107,803.43 | 23,994 | Direct | โ | View Details | |
CSO & EVP, Head of Research | Common Stock | โ | Mar 2, 2026 | Sale | 100 | $328.71 | $32,871.00 | 23,894 | Direct | โ | View Details | |
CSO & EVP, Head of Research | Common Stock | โ | Mar 2, 2026 | Sale | 170 | $329.71 | $56,050.70 | 23,724 | Direct | โ | View Details | |
CSO & EVP, Head of Research | Common Stock | โ | Mar 2, 2026 | Sale | 81 | $330.85 | $26,798.85 | 23,643 | Direct | โ | View Details | |
CSO & EVP, Head of Research | Common Stock | โ | Mar 2, 2026 | Sale | 94 | $331.93 | $31,201.42 | 23,549 | Direct | โ | View Details | |
CSO & EVP, Head of Research | Common Stock | โ | Mar 2, 2026 | Sale | 37 | $332.64 | $12,307.68 | 23,512 | Direct | โ | View Details | |
CSO & EVP, Head of Research | Common Stock | โ | Mar 3, 2026 | Sale | 289 | $316.55 | $91,482.95 | 23,223 | Direct | โ | View Details | |
CSO & EVP, Head of Research | Common Stock | โ | Mar 3, 2026 | Sale | 282 | $318.62 | $89,850.84 | 22,941 | Direct | โ | View Details | |
CSO & EVP, Head of Research | Common Stock | โ | Mar 3, 2026 | Sale | 722 | $320.51 | $231,408.22 | 22,219 | Direct | โ | View Details | |
CSO & EVP, Head of Research | Common Stock | โ | Mar 3, 2026 | Sale | 359 | $321.58 | $115,447.22 | 21,860 | Direct | โ | View Details | |
CSO & EVP, Head of Research | Stock Option (right to buy) | Derivative | Mar 2, 2026 | Grant/Award | 8,105 | $0.00 | $0.00 | 8,105 | Direct | โ | View Details |